If promising results on a skin cancer vaccine from Moderna and Merck lead to a new launch, the Covid-19 era darling's stock ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 8.8% in the afternoon session after the company, ...

The vaccine maker is expanding beyond its COVID-focused offerings.

Moderna MRNA announced that it submitted regulatory filings seeking approval for its seasonal influenza vaccine mRNA-1010 across the United States, European Union, Canada and Australia. These filings ...

Bayer has filed patent infringement lawsuits against COVID-19 vaccine makers Pfizer, BioNTech, Moderna, and Johnson & Johnson. The company claims these firms misused mRNA technology pioneered by ...

Bayer's Monsanto has sued Pfizer, BioNTech and Moderna for allegedly misusing its messenger RNA technology in COVID vaccines.

(The Hill) — Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research into a potential bird flu mRNA vaccine, helping to recover ...

(NASDAQ:MRNA) today provided an update on regulatory submissions for its investigational seasonal influenza vaccine, ...

Filed in a Delaware federal court, the lawsuits claim the companies copied technology developed by Bayer's subsidiary, Monsanto, in the 1980s. This pioneering work, originally designed to strengthen ...

The overall sentiment of these big-money traders is split between 54% bullish and 36%, bearish. Out of all of the special options we uncovered, 11 are puts, for a total amount of $951,480, and 11 are ...

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Moderna compared ...